A Service For Professionals Friday, September 22, 2017
Contact (202) 540-8337

Company News Today

A Service For Professionals Friday, September 22, 2017 11594 Sources 405,458,916 Articles 3,235,762 Readers
Contact (202) 540-8337

Breaking News

< >

Global Biosimulation Market 2017 Share, Trend, Segmentation and Forecast to 2022

Global Biosimulation Market is expected to exceed $2.2 billion in 2020 with a CAGR 15.5% by 2020

PUNE , MAHARASHTRA, INDIA, July 20, 2017 /EINPresswire.com/ -- Biosimulation Industry

Description

Wiseguyreports.Com Adds “Biosimulation -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database

Global Biosimulation Market is expected to exceed $2.2 billion in 2020 with a CAGR 15.5% during 2015-2020. Rise in adoption of drug discovery and development and success in precision dosing are expected to boost global Biosimulation market. Biosimulation applications such as preclinical testing, clinical trials, target identification and validation, lead identification and optimization are widely adopted. These applications enable to provide faster and more certain results compared to conventional techniques as a result it is widely adopted across the globe. The technological advancement and innovation in Biosimulation products and applications enable to reduce the number of clinical studies for drug development. Model-based drug development reduce the clinical studies and offer better results. Biosimulation has huge contribution in personalized medicines which are adopted widely for better patient care. Due to the advancement in biosimulation the traditional one size fits all concept is replaced by personalized medicines. Biosimulation models enable to find better protection against various diseases such as tumor and other cancer cases through precise dozing. As a result it saves time, effort and money for drug development for many diseases. 

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/1509647-global-biosimulation-market-research-and-analysis-2015-2021

Biosimulation technology offers virtual clinical trial population for pediatric, elderly and other group of patients. It enables to perform better clinical trials and reduce the time and effort for drug discovery and development. Technological advancement and innovation in biosimulation market enables to penetrate in emerging economies such as China, India, Japan and Korea. Biosimulation market by application such as preclinical testing, clinical trials, target identification and validation, lead identification and optimization are enhanced through research and development. Biosimulation market by product includes Pharmacokinetic/Pharmacodynamic (PK/PD), Molecular Modelling, Toxicity Prediction Software. These products enables to avoid drug-drug interaction studies, evaluating, genetic differences, predicting human doses and handling of drugs. 

Geographical Insights 

North America generates highest revenues across the globe due to huge adoption of Biosimulation technology and highest rate of healthcare spending followed by Europe. Untapped APAC region such as China, India, Japan and Korea are the most emerging economies and expected to create huge opportunity for Biosimulation Market. Improved healthcare spending, infrastructure development and favorable government policies are the key factors which are expected to drive the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Strategic Recommendations, Key Company Analysis, GAP Analysis, Key Findings, Market Estimations, Market Insights, Analyst Insights and predictive analysis of the market. Global Biosimulation Market is expected to grow significantly due to rise in adoption of drug discovery and development, personalized medicine and success of precision dozing. The results of research & development and critical FDA approvals enable the Biosimulation Market to grow fast. Funding from government and private players are also key factors to drive the Global Biosimulation Market. However, high cost of Global Biosimulation products and application are concern for the growth of Biosimulation Market. The report also covers parametric analysis, historical analysis and Pipeline Analysis. 

Competitive Insights: The key players of Global Biosimulation Market includes Certara Us, Inc., Simulation Plus Inc., Dassault Systèmes SA, Schrodinger Inc., Advanced Chemistry Development, Inc., Chemical Computing Group, Inc., Entelos Holding Corporation, Genedata Ag, Physiomics PLC, Rhenovia Pharma Ltd, Accelrys Inc., Leadscope, Insilico Biosciences, Compugen, Nimbus Healthcare, Insilico Biosciences Inc., Inhibox, Johnson & Johnson, Biovia, Leadinvent Technologies and so on. 

Market Segmentation: 

Global Biosimulation Market is segmented on the basis of application, product, end user and region. Global Biosimulation Market by application and end user has significant contribution in generating huge revenues across the globe. The Global Biosimulation Market by product such as PK/PD modelling and simulation, molecular modelling are widely adopted across the globe. Global simulation market by application such as drug development, preclinical testing, drug discovery and so on.

Leave a Query @ https://www.wiseguyreports.com/enquiry/1509647-global-biosimulation-market-research-and-analysis-2015-2021

Table of Content

REPORT SUMMARY 
    1.1. RESEARCH METHODS AND TOOLS 
    1.2. MARKET BREAKDOWN 
      1.2.1. BY SEGMENTS 
      1.2.2. BY GEOGRAPHY 
      1.2.3. BY STAKEHOLDERS 
      1.2.4. EXCEPTIONS 
MARKET OVERVIEW AND INSIGHTS 
    2.1. DEFINITION 
    2.2. GAP ANALYSIS 
    2.3. HISTORICAL ANALYSIS 
    2.4. CURRENT MARKET TRENDS 
    2.5. PIPELINE ANALYSIS 
    2.6. ANALYST INSIGHT 
      2.6.1. KEY FINDINGS 
      2.6.2. RECOMMENDATION 
      2.6.3. CONCLUSION 
    2.7. REGULATION 
      2.7.1. REGULATIONS ON CLINICAL TRIALS 
              2.7.1.1.1. UNITED STATES 
              2.7.1.1.2. EUROPEAN UNION 
              2.7.1.1.3. CHINA 
              2.7.1.1.4. INDIA 
              2.7.1.1.5. REST OF THE WORLD 
          2.7.1.2. DRUG AND DEVICE REGULATIONS 
              2.7.1.2.1. UNITED STATES 
              2.7.1.2.2. EUROPEAN UNION 
              2.7.1.2.3. CHINA 
              2.7.1.2.4. INDIA 
              2.7.1.2.5. REST OF THE WORLD 
....

COMPANY PROFILES 
    8.1. CERTARA US, INC. 
      8.1.1. INTRODUCTION 
      8.1.2. CERTARA PRODUCT PORTFOLIO 
      8.1.3. CERTARA RECENT ACTIVITIES 
      8.1.4. CERTARA SWOT ANALYSIS 
    8.2. SIMULATION PLUS INC 
      8.2.1. INTRODUCTION 
      8.2.2. SIMULATION PLUS INC PRODUCT PORTFOLIO 
      8.2.3. SIMULATION PLUS INC RECENT ACTIVITIES 
      8.2.4. SIMULATION PLUS INC SWOT ANALYSIS 
    8.3. DASSAULT SYSTÈMES SA 
      8.3.1. INTRODUCTION 
      8.3.2. DASSAULT SYSTEMS SA PRODUCT PORTFOLIO 
      8.3.3. DASSAULT SYSTEMS SA RECENT ACTIVITIES 
      8.3.4. DASSAULT SYSTEMS SA SWOT ANALYSIS 
    8.4. SCHRÖDINGER INC. 
      8.4.1. INTRODUCTIONSS 
      8.4.2. SCHRODINGER INC PRODUCT PORTFOLIO 
      8.4.3. SCHRODINGER INC RECENT ACTIVITIES 
      8.4.4. SCHRODINGER INC SWOT ANALYSIS 
    8.5. ADVANCED CHEMISTRY DEVELOPMENT, INC. 
      8.5.1. INTRODUCTION 
      8.5.2. ADVANCED CHEMISTRY DEVELOPMENT PRODUCT PORTFOLIO 
      8.5.3. ADVANCED CHEMISTRY DEVELOPMENT RECENT ACTIVITIES 
      8.5.4. ADVANCED CHEMISTRY DEVELOPMENT SWOT ANALYSIS 
    8.6. CHEMICAL COMPUTING GROUP, INC. 
      8.6.1. INTRODUCTION 
      8.6.2. CHEMICAL COMPUTING GROUP, INC PRODUCT PORTFOLIO 
      8.6.3. CHEMICAL COMPUTING GROUP, INC RECENT ACTIVITIES 
      8.6.4. CHEMICAL COMPUTING GROUP, INC SWOT ANALYSIS 
    8.7. ENTELOS HOLDING CORPORATION 
      8.7.1. INTRODUCTION 
      8.7.2. ENTELOS HOLDING CORPORATION PRODUCT PORTFOLIO 
      8.7.3. ENTELOS HOLDING CORPORATION RECENT ACTIVITIES 
      8.7.4. ENTELOS HOLDING CORPORATION SWOT ANALYSIS 
    8.8. GENEDATA AG 
      8.8.1. INTRODUCTION 
      8.8.2. GENEDATA AG PRODUCT PORTFOLIO 
      8.8.3. GENEDATA AG RECENT ACTIVITIES 
      8.8.4. GENEDATA AG SWOT ANALYSIS 
    8.9. PHYSIOMICS PLC 
      8.9.1. INTRODUCTION 
      8.9.2. PHYSIOMICS PLC PRODUCT PORTFOLIO 
      8.9.3. PHYSIOMICS PLC RECENT ACTIVITIES 
      8.9.4. PHYSIOMICS PLC SWOT ANALYSIS 
    8.10. RHENOVIA PHARMA LTD 
      8.10.1. INTRODUCTION 
      8.10.2. RHENOVIA PRODUCT PORTFOLIO 
      8.10.3. RHENOVIA RECENT ACTIVITIES 
      8.10.4. RHENOVIA SWOT ANALYSIS 
    8.11. ACCELRYS INC. 
      8.11.1. INTRODUCTION 
      8.11.2. ACCELRYS INC PRODUCT PORTFOLIO 
      8.11.3. ACCELRYS INC RECENT ACTIVITIES 
      8.11.4. ACCELRYS INC SWOT ANALYSIS 

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1509647

Continued...                                                                                            

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) 

NORAH TRENT
Wise Guy Reports
+91 841 198 5042
email us here

Powered by EIN Presswire